AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16799824 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial view
Number of subjects: 30
Study 12712239 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) 24 micro g/kg per hour for 96 h
Number of subjects: 1271
Study 12712239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1271
Study 12712239 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 1271
Study 10344368 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol with cyclic addition of noretisterone acetate (n = 13)
Number of subjects: 23
Study 8786543 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.4-0.5 mg)
Number of subjects: 7
Study 8786543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8786543 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.2 or 0.4 mg)
Number of subjects: 7
Study 8786543 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 7
Study 1956490 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulosic membranes (Cuprophan, CUP)
Number of subjects: 20
Study 1956490 — intervention group
Group type: COMPARATOR
Intervention: Synthetic polyacrilonitrile membranes (PAN AN-69)
Number of subjects: 20
Study 7086102 — intervention group
Group type: EXPERIMENTAL
Intervention: pH 1 citric acid
Number of subjects: 13
Study 7086102 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mM hydrochloric acid
Number of subjects: 13
Study 7086102 — intervention group
Group type: EXPERIMENTAL
Intervention: pH 7 sodium citrate
Number of subjects: 13
Study 7086102 — intervention group
Group type: EXPERIMENTAL
Intervention: pH 0.85 hydrochloric acid
Number of subjects: 13
Study 7086102 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control)
Number of subjects: 13
Study 30124989 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg) plus standard triple antiemetic therapy
Number of subjects: 690
Study 30124989 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard triple antiemetic therapy
Number of subjects: 690
Study 26247548 — intervention group
Group type: EXPERIMENTAL
Intervention: Climbing intervention (10 sessions in 8 weeks, at least once a week for a minimum duration of 1 hour)
Number of subjects: 30
Study 26247548 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 25187581 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular injection
Number of subjects: 111
Study 22753306 — intervention group
Group type: EXPERIMENTAL
Intervention: Blacks (age-adjusted HR=1.45)
Number of subjects: 156143
Study 22753306 — intervention group
Group type: COMPARATOR
Intervention: Whites (age-adjusted HR=1.00, reference group)
Number of subjects: 156143
Study 22753306 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanics (age-adjusted HR=0.72)
Number of subjects: 156143
Study 22753306 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian/Pacific Islanders (age-adjusted HR=0.44)
Number of subjects: 156143
Study 22753306 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for household income (HR=0.97) and diabetes mellitus (HR=0.89) in blacks
Number of subjects: 156143
Study 22753306 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for traditional risk factors, socioeconomic status, lifestyle, and access-to-care variables
Number of subjects: 156143
Study 20545502 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT)
Number of subjects: 120
Study 20545502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 120
Study 20545502 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication (ADM)
Number of subjects: 120
Study 18468378 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug reimbursement rate reduction policy
Number of subjects: 0
Study 15998783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic polypeptide (PP) infusion at 0.75 or 2.25 pmol/kg.min
Number of subjects: 14
Study 15998783 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 14
Study 15998783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic polypeptide (PP) infusion at 2.25 pmol/kg.min
Number of subjects: 14
Study 12401734 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring blood glucose device with standardized counseling
Number of subjects: 0
Study 12401734 — intervention group
Group type: COMPARATOR
Intervention: Control group with nonstandardized counseling
Number of subjects: 0
Study 12401734 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring blood glucose device
Number of subjects: 0
Study 10419803 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal Uterine Doppler Velocimetry (Ut.DV) defined as (left and right systolic)/diastolic ratio >2.6 and diastolic notching
Number of subjects: 90
Study 10419803 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Uterine Doppler Velocimetry (Ut.DV)
Number of subjects: 90
Study 10419803 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal Uterine Doppler Velocimetry (Ut.DV) in normotensive and hypertensive pregnancies
Number of subjects: 90
Study 7568635 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 0.2 mg/kg
Number of subjects: 60
Study 7568635 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 0.3 mg/kg
Number of subjects: 60
Study 7568635 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam 0.026 mg/kg
Number of subjects: 60
Study 7568635 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam 0.038 mg/kg
Number of subjects: 60
Study 7568635 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 2247550 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention directed to right-field flashes
Number of subjects: 20
Study 2247550 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention directed to left-ear tones
Number of subjects: 20
Study 2247550 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention directed to either modality
Number of subjects: 20
Study 6446691 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminooxyacetic acid (AOAA) at a dosage of 2 mg per kilogram per day
Number of subjects: 7
Study 6446691 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminooxyacetic acid (AOAA) for 4 months
Number of subjects: 7
Study 6446691 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminooxyacetic acid (AOAA)
Number of subjects: 7
Study 6446691 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 7
Study 6408155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine (200 mg po)
Number of subjects: 12
Study 6408155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30502656 — intervention group
Group type: EXPERIMENTAL
Intervention: 1975 Japanese diet (JD)
Number of subjects: 21
Study 30502656 — intervention group
Group type: COMPARATOR
Intervention: Modern Japanese diet (MD)
Number of subjects: 21
Study 29526832 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10142
Study 29526832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study 27114361 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component educational intervention including online lectures, videos, and hands-on experience.
Number of subjects: 89
Study 27114361 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture-based education (Control group).
Number of subjects: 89
Study 27114361 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation workshop for intervention group participants.
Number of subjects: 89
Study 27114361 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and post-intervention surveys for both groups.
Number of subjects: 89
Study 27114361 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual online clinical exam for all participants.
Number of subjects: 89
Study 27114361 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported data on referral patterns.
Number of subjects: 89
Study 24895878 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (n = 167)
Number of subjects: 656
Study 24895878 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tissue-plasminogen activator (IV tPA) (n = 52)
Number of subjects: 656
Study 24895878 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (n = 190)
Number of subjects: 656
Study 24895878 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tissue-plasminogen activator (IV tPA) (n = 92)
Number of subjects: 656
Study 24895878 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (n = 46)
Number of subjects: 656
Study 24895878 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tissue-plasminogen activator (IV tPA) (n = 23)
Number of subjects: 656
Study 22848340 — intervention group
Group type: EXPERIMENTAL
Intervention: New mother-child play activity program (10 min a day, 5 days a week for 3 months)
Number of subjects: 238
Study 22848340 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 238
Study 20530662 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with ultrasound central anterior chamber depth (cACD) < 2.53 mm
Number of subjects: 4597
Study 20530662 — intervention group
Group type: COMPARATOR
Intervention: No screening (control group)
Number of subjects: 4597
Study 18781875 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 0
Study 18781875 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (Meningococcal conjugate vaccine against serogroup C)
Number of subjects: 0
Study 15838889 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (TAC + corticosteroids)
Number of subjects: 180
Study 15838889 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (TAC + corticosteroids + AZA)
Number of subjects: 180
Study 12492189 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Stiffness Colonoscope (VSC)
Number of subjects: 467
Study 12492189 — intervention group
Group type: COMPARATOR
Intervention: Conventional Colonoscope (CC)
Number of subjects: 467
Study 10458221 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 200 mg/m2 and cyclophosphamide 4 g/m2 with progenitor cell and filgrastim support every 28 days (n = 79) or 21 days (n = 20)
Number of subjects: 99
Study 7734907 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet
Number of subjects: 58
Study 7734907 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 58
Study 2140439 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 35
Study 2140439 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 35
Study 2140439 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 7318882 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 3 mg/kg intravenously
Number of subjects: 57
Study 7318882 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.3 mg/kg for sleep induction
Number of subjects: 57
Study 7318882 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 57
Study 7318882 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 57
Study 31563384 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking meditation (WM) for 8 weeks, 30 min/day, 3 days/week
Number of subjects: 58
Study 31563384 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study 29208829 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification (PKE) in Group A (pupil size <5 mm)
Number of subjects: 150
Study 29208829 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification (PKE) in Group B (pupil size 5‐7 mm)
Number of subjects: 150
Study 29208829 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification (PKE) in Group C (pupil size >7 mm)
Number of subjects: 150
Study 26620555 — intervention group
Group type: EXPERIMENTAL
Intervention: Transumbilical single incision plus one port laparoscopic surgery (SILS plus one)
Number of subjects: 198
Study 23252715 — intervention group
Group type: EXPERIMENTAL
Intervention: Group LI: ultrasound-guided SNB using long axis view of SN and in-plane insertion of the needle
Number of subjects: 120
Study 23252715 — intervention group
Group type: COMPARATOR
Intervention: Group SI: ultrasound-guided SNB using short axis view of SN and in-plane insertion of the needle
Number of subjects: 120
Study 23252715 — intervention group
Group type: COMPARATOR
Intervention: Group LO: ultrasound-guided SNB using long axis view of SN and out-of-plane insertion of the needle
Number of subjects: 120
Study 23252715 — intervention group
Group type: COMPARATOR
Intervention: Group SO: ultrasound-guided SNB using short axis view of SN and out-of-plane insertion of the needle
Number of subjects: 120
Study 21756843 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitative online education (N = 29) for five weeks with professional audiologist contact
Number of subjects: 59
Study 21756843 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 30) - online discussion forum without audiologist contact
Number of subjects: 59
Study 18713091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation programme
Number of subjects: 78
Study 18713091 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pulmonary rehabilitation)
Number of subjects: 78
Study 16789980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous albumin
Number of subjects: 40
Study 16789980 — intervention group
Group type: COMPARATOR
Intervention: Noradrenaline
Number of subjects: 40
Study 14504869 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibin B <1200 pg/ml
Number of subjects: 31
Study 14504869 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibin B >1200 pg/ml
Number of subjects: 31
Study 14504869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulus oocyte complexes
Number of subjects: 31
Study 14504869 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaphase II oocytes
Number of subjects: 31
Study 14504869 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibin B
Number of subjects: 31
Study 14504869 — intervention group
Group type: COMPARATOR
Intervention: Classical parameters (Estrogen, FSH, LH)
Number of subjects: 31
Study 11014391 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (MO) plus Flumazenil (FL) (MO 2 mg + FL 0.2 mg)
Number of subjects: 36
Study 11014391 — intervention group
Group type: COMPARATOR
Intervention: Morphine (MO) only (MO 2 mg)
Number of subjects: 36
Study 9048715 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic fatigue syndrome without psychiatric comorbidity
Number of subjects: 36
Study 9048715 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study 9048715 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic fatigue syndrome with psychiatric disease
Number of subjects: 36
Study 8514472 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride injection after cyst aspiration
Number of subjects: 154
Study 8514472 — intervention group
Group type: COMPARATOR
Intervention: Control group (aspirated without minocycline hydrochloride injection)
Number of subjects: 154
Study 3545942 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (intramuscularly administered)
Number of subjects: 40
Study 3545942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29893791 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 63
Study 29893791 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 63
Study 28315134 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic carrier screening
Number of subjects: 240
Study 28315134 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistical issues related to genomic carrier screening
Number of subjects: 240
Study 25660821 — intervention group
Group type: EXPERIMENTAL
Intervention: Geranylgeranylacetone
Number of subjects: 40
Study 25660821 — intervention group
Group type: COMPARATOR
Intervention: Control (diclofenac sodium only)
Number of subjects: 40
Study 23536417 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercise (PRE)
Number of subjects: 51
Study 23536417 — intervention group
Group type: COMPARATOR
Intervention: Stretching, balance, and strengthening exercise program (mFC)
Number of subjects: 51
Study 21406717 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 241
Study 21406717 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 241
Study 21406717 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine plus cyclophosphamide (FC)
Number of subjects: 241
Study 18163431 — intervention group
Group type: EXPERIMENTAL
Intervention: Keys to Caregiving Program
Number of subjects: 13
Study 18163431 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study 16552548 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteochondral autologous transplantation (OAT)
Number of subjects: 57
Study 16552548 — intervention group
Group type: COMPARATOR
Intervention: Microfracture (MF)
Number of subjects: 57
Study 16552548 — intervention group
Group type: EXPERIMENTAL
Intervention: OAT
Number of subjects: 57
Study 16552548 — intervention group
Group type: COMPARATOR
Intervention: MF
Number of subjects: 57
Study 14667889 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (25 mg/d orally)
Number of subjects: 20
Study 12666979 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose doxycycline (20 mg, b.i.d.)
Number of subjects: 15
Study 12666979 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive filler; starchflour, b.i.d.)
Number of subjects: 15
Study 8617118 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole delivered orally
Number of subjects: 10
Study 8617118 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole delivered via nasogastric tube
Number of subjects: 10
Study 1571877 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to Quit (TTQ) self-help cessation program
Number of subjects: 307
Study 1571877 — intervention group
Group type: COMPARATOR
Intervention: Control group (community smoking cessation resources)
Number of subjects: 307
Study 3909374 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 300 mg daily
Number of subjects: 151
Study 3909374 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 100 mg twice daily or 150 mg at night
Number of subjects: 151
Study 3909374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 30298416 — intervention group
Group type: EXPERIMENTAL
Intervention: Low flow rate (1 L/min) for induction followed by high flow rate (10 L/min) for maintaining 12 mmHg pneumoperitoneum (group A)
Number of subjects: 140
Study 30298416 — intervention group
Group type: COMPARATOR
Intervention: Continuous high flow rate group (group B)
Number of subjects: 140
Study 29995726 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic negative pressure wound therapy
Number of subjects: 166
Study 29995726 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical dressings
Number of subjects: 166
Study 27697330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (study formula)
Number of subjects: 150
Study 27697330 — intervention group
Group type: COMPARATOR
Intervention: Nutritional supplementation (study formula) in 'good' consumers initially randomized to placebo
Number of subjects: 150
Study 27697330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (study formula) in 'poor' consumers
Number of subjects: 150
Study 25299647 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard opt-in invitation
Number of subjects: 1172
Study 25299647 — intervention group
Group type: EXPERIMENTAL
Intervention: Active choice invitation
Number of subjects: 1172
Study 25299647 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced active choice invitation
Number of subjects: 1172
Study 22009219 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective photocoagulation (S‐PC)
Number of subjects: 69
Study 22009219 — intervention group
Group type: COMPARATOR
Intervention: Non-photocoagulation (non-PC group)
Number of subjects: 69
Study 22009219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 69
Study 20361377 — intervention group
Group type: EXPERIMENTAL
Intervention: MESH catheter
Number of subjects: 64
Study 20361377 — intervention group
Group type: COMPARATOR
Intervention: Control group (three-dimensional mapping system guided ablation)
Number of subjects: 64
Study 20361377 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 17981375 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at different intensities (67/0; 93.8/0; and 93.8 m min(‐1)/2.5% slope)
Number of subjects: 58
Study 17981375 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at the highest intensity
Number of subjects: 58
Study 17981375 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking EE estimated using MET codes
Number of subjects: 58
Study 17981375 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at ground level
Number of subjects: 58
Study 16095529 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP-1 levels in children with ILD
Number of subjects: 25
Study 16095529 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR2+ T cells in children with ILD
Number of subjects: 25
Study 16095529 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP-1 levels in children with lung fibrosis
Number of subjects: 25
Study 16095529 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR2+ T cells in children with lung fibrosis
Number of subjects: 25
Study 16095529 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of MCP-1 and CCR2+ T cells with lung function
Number of subjects: 25
Study 12417542 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 4284
Study 12417542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4284
Study 10511436 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 18
Study 10511436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 18